1. Introduction {#sec1}
===============

The causative agent of melioidosis, *Burkholderia pseudomallei*, is endemic in the Northern part of Australia and Southeast Asia including Malaysia. Acute melioidosis may present as localized or septicaemic infections and can be fatal if left untreated. It was the common cause of community-acquired pneumonia in Northeastern Thailand and was attributed as the cause of fatal community-acquired bacteremic pneumonia in Northern Australia \[[@B1], [@B2]\]. Latent infection may remain asymptomatic for years only to be reactivated from a latent focus when the host is immunocompromised. Therefore, it is important to treat melioidosis with prolonged course of antibiotics so as to avoid disease relapses which are commonly associated with short courses of antibiotics. Some patients may default treatment or take improper dosage of antibiotics because of the long duration of treatment, and this may contribute to the relapse or the development of resistance.

*Burkholderia pseudomallei* is intrinsically resistant to a wide range of antibiotics which include some *β*-lactam antibiotics, aminoglycosides, and macrolides. The antibiotics that are currently being used for the therapy of melioidosis are ceftazidime, imipenem, meropenem, amoxicillin/clavulanate, cefoperazone/sulbactam, trimethoprim-sulfamethoxazole (TMP-SMX), doxycycline, and chloramphenicol. The antibiotic regime for the treatment of melioidosis varies from one country to another. In Malaysia, ceftazidime alone, or in combination with TMP-SMX or cefoperazone/sulbactam alone or in combination with TMP-SMX or imipenem, is the recommended antibiotic of choice for the intensive phase of treatment followed by oral TMP-SMX plus doxycycline or amoxicillin/clavulanate in the maintenance phase \[[@B3]\]. The development of resistance of *Burkholderia pseudomallei* to some of these antibiotics has been reported in neighbouring countries such as Singapore and Thailand \[[@B4], [@B5]\]. Reports on the antibiotic susceptibility of *Burkholderia pseudomallei* in Malaysia have been limited to a few selected antibiotics and a smaller number of tested strains and from restricted demographic areas \[[@B6], [@B7]\].

Therefore, the aim of the study was to determine the in vitro antibiotic susceptibility patterns of clinical isolates of *Burkholderia pseudomallei* to a panel of antibiotics used for the treatment of melioidosis and also to the potential alternative antibiotics such as tigecycline, ampicillin/sulbactam, and piperacillin/tazobactam.

2. Materials and Methods {#sec2}
========================

2.1. Bacterial Isolates {#sec2.1}
-----------------------

A total of 170 *Burkholderia pseudomallei* nonrepeat clinical isolates were collected from the year 2001 until the year 2009, from the microbiology laboratories of 29 government hospitals situated in 11 out of 14 states in Malaysia ([Table 1](#tab1){ref-type="table"}). These isolates were sent from these hospitals for the confirmation of identification at the Bacteriology Unit, Institute for Medical Research. Species identification was carried out by Gram-staining, motility, API 20NE (bioMèrieux), and polymerase chain reaction technique using specific 16rRNA primers as described by Brook et al. 1997 \[[@B8]\]. The strains were stored at −80°C in 20% glycerol and were revived by subculturing onto blood agar plates before being further used.

2.2. Antibiotic Susceptibility Testing {#sec2.2}
--------------------------------------

Minimum inhibitory concentrations (MIC) of the antibiotics were determined by *E*-test (bioMèrieux) following the manufacturer\'s instructions. Eleven antibiotics were tested, namely, ceftazidime, imipenem, meropenem, amoxicillin/clavulanic acid, TMP-SMX, ciprofloxacin, doxycycline, chloramphenicol, piperacillin/tazobactam, ampicillin/sulbactam, and tigecycline.

A 0.5 McFarland suspension was made for each bacterial isolates and then inoculated on Mueller-Hinton (MH) (BD) agar. The *E*-test strips of each antibiotic were placed on the MH agar and incubated overnight at 37°C. The zones of inhibition were noted after 18 hours of incubation. The MIC (*μ*g/mL) interpretation for susceptible (*s*), intermediate (*i*), and resistant (*r*) for amoxicillin-clavulanic acid (*s* ≤ 8/4, *i*  16/8, *r* ≥ 32/16), ceftazidime (*s* ≤ 8, *i*  16, *r* ≥ 32), imipenem (*s* ≤ 4, *i*  8, *r* ≥ 16), doxycycline (*s* ≤ 4, *i*  8, *r* ≥ 16), and TMP-SMX (*s* ≤ 2/38, -, *r* ≥ 4/76) was carried out following the CLSI approved guideline M45-A2 \[[@B9]\]. For ciprofloxacin (*s* ≤ 1, *i*  2, *r* ≥ 4), chloramphenicol (*s* ≤ 8, *i*  16, *r* ≥ 32), piperacillin/tazobactam (*s* ≤ 16/4, *i*  32/4--64/4, *r* ≥ 128/4), and ampicillin/sulbactam (*s* ≤ 8/4, *i*  16/8, *r* ≥ 32/16), the MIC (*μ*g/mL) for Enterobacteriaceae was referred \[[@B10]\]. For tigecycline, the US FDA approved breakpoints for Enterobacteriaceae were used (*s* ≤ 2, *i*  4, *r* ≥ 8). For meropenem, the interpretative criteria outlined by the *E*-test manufacturer for aerobes were followed (*s* ≤ 4, *i*  8, *r* ≥ 16). Any values which were in between the sensitive and resistant breakpoints were interpreted as intermediates. *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as controls.

3. Results {#sec3}
==========

All strains were sensitive to meropenem and piperacillin/tazobactam. Sensitivity to ceftazidime, imipenem, amoxicillin/clavulanic acid, ampicillin/sulbactam, and doxycycline was noted in 169 (99.4)% of the isolates. One isolate was shown to have heterogenous population with ceftazidime susceptibility of 8 *μ*g/mL and ceftazidime resistance of ≥256 *μ*g/mL. This strain, however, remained susceptible to other antibiotics. The isolate that was intermediately resistant to imipenem (MIC 6 *μ*g/mL) was also resistant to amoxicillin/clavulanic acid and ampicillin/sulbactam. For chloramphenicol and TMP-SMX, 164 (96.5%) and 153 (90%) of the strains were susceptible, respectively. Only 72 (42.3%) isolates were susceptible to ciprofloxacin while 94 (55.3%) isolates showed intermediate resistance with MIC of 1.5--3.0 *μ*g/mL. Susceptibility to tigecycline was observed in 110 isolates (64.7%) while intermediate resistance was noted in 59 (34.7%) of the isolates. One isolate was resistant to tigecycline at the MIC of 8.0 *μ*g/mL.

The minimum concentration of antibiotics that inhibited 50% (MIC~50~) and 90% (MIC~90~) of the isolates and the range of MICs of the tested antibiotics were shown in [Table 2](#tab2){ref-type="table"}. The MIC~90~ of most of the antibiotics were within the range of 0.38 to 4.0 *μ*g/mL. Chloramphenicol was shown to have higher MIC~50~ and MIC~90~ values than the other antibiotics (MIC~50~, 6.0 *μ*g/mL; MIC~90~ 8.0 *μ*g/mL). Imipenem (MIC~50,~ 0.38 *μ*g/mL; MIC~90~, 0.38 *μ*g/mL) was more active towards these strains than meropenem (MIC~50~, 0.75 *μ*g/mL and MIC~90~, 1.0 *μ*g/mL).

The resistance pattern observed among these strains was mainly monoresistance where 7 strains showed resistance to a single antibiotic, either to ceftazidime (1 strain), ciprofloxacin (1 strain), or trimethoprim/sulfamethoxazole (5 strains). Two strains showed resistance to 2 different types of antibiotics (1 isolate to ciprofloxacin & trimethoprim/sulfamethoxazole; 1 strain to amoxicillin/clavulanic acid and ampicillin/sulbactam). One strain showed multiple resistances to 4 antibiotics namely ciprofloxacin, chloramphenicol, trimethoprim/sulfamethoxazole, and tigecycline and intermediate resistance to doxycycline.

4. Discussion {#sec4}
=============

This study showed that the local strains were highly susceptible to meropenem and piperacillin/tazobactam. For ceftazidime, imipenem, amoxicillin/clavulanic acid, and doxycycline, only 0.6% of the isolate was resistant to these antibiotics. A highly resistant subpopulation of ceftazidime resistance was detected in one of the strain. This was a blood isolate from a patient who had no past record of melioidosis and had passed away a day after admission before the culture result was obtained. Primary resistance to ceftazidime is rare and studies had documented that the development of resistance emerge mainly during treatment \[[@B11], [@B12]\].

The susceptibility to trimethoprim/sulfamethoxazole is slightly lower compared to 97.5% in the another local study on 80 *Burkholderia pseudomallei* \[[@B6]\]. Only 4.0% of our isolates was resistant to trimethoprim/sulfamethoxazole compared to 13% resistance rate in Thailand \[[@B13]\]. Our local strains were also highly susceptible to chloramphenicol. An open label study in Thailand had shown that the combination of chloramphenicol, TMP-SMX, and doxycycline was associated with higher adverse effect compared to TMP-SMX and doxycycline only \[[@B14]\]. Chloramphenicol was not included in the maintenance therapy of melioidosis in Malaysia \[[@B3]\].

The antibiotic susceptibility rate of ciprofloxacin was low at 42.3%, and 90% of the isolates were inhibited at the intermediate MIC value of 2 *μ*g/mL, which implied that ciprofloxacin was less effective towards these strains. Fluoroquinolones have been shown to be less effective clinically \[[@B15], [@B16]\].

A study on the activity of tigecycline against *Burkholderia pseudomallei* in Thailand showed low MIC~50~ and MIC~90~ (0.5 *μ*g/mL and 2.0 *μ*g/mL) \[[@B17]\]. This finding is similar to another study in Malaysia \[[@B7]\]. In contrast, the isolates tested in this study were less susceptible to tigecycline, where higher MIC~50~ and MIC~90~ values (0.75 *μ*g/mL and 4.0 *μ*g/mL) were observed. The susceptibility of tigecycline was only 64.7%, and 34.7% of the strains were inhibited at the intermediate range of MIC of 3.0--6.0 *μ*g/mL. This is in concordance with another study in Australia, where 85.5% of the isolates were inhibited at an intermediate MIC of 4.0 *μ*g/mL with lower susceptibility rate of 14.5% \[[@B18]\].

The isolate that was intermediately resistant to imipenem with MIC 6 *μ*g/mL, also had co-resistance to amoxicillin/clavulanic acid and ampicillin/sulbactam. This isolate was susceptible to meropenem at MIC 1.5 *μ*g/mL. The MIC~50~ and MIC~90~ of meropenem were noted to be higher than those in imipenem; however, meropenem is still effective against all the strains tested. In Malaysia, meropenem or imipenem has been used for severe infection or in the event of treatment failure with ceftazidime. All the multiply resistant strains were still susceptible to ceftazidime but some of these strains were resistant to the antibiotics used in the maintenance therapy. The mechanism of resistance of these isolates will be further studied.

In conclusion, the *Burkholderia pseudomallei* isolates from Malaysia were highly susceptible to the antibiotics used in the treatment of melioidosis namely ceftazidime, trimethoprim/sulfamethoxazole, imipenem, meropenem, amoxicillin-clavulanate, and doxycycline. Ciprofloxacin and tigecycline were not active in vitro against these isolates. The presence of isolates that were resistant to the antibiotics used for maintenance therapy is of concern because this could affect the treatment outcome and may lead to the relapse of infection.
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###### 

The information on the strains used in this study.

  Lab ID      Year isolated   State                 Sex   Source
  ----------- --------------- --------------------- ----- ------------------
  RZ 14/01    2001            Negeri Sembilan       m     wound swab
  RZ 16/01    2001            Negeri Sembilan       m     urine
  RZ 21/01    2001            Perak                 f     blood
  RZ 31/01    2001            Selangor              f     NA
  RZ 37/01    2001            Perak                 m     sputum
  RZ 116/01   2001            Kedah                 m     pus
  RZ 166/01   2001            Perak                 m     blood
  RZ 169/01   2001            Perak                 m     blood
  RZ 191/01   2001            Perak                 f     blood
  RZ 12/02    2002            Negeri Sembilan       f     pus
  RZ 50/02    2002            Johor                 m     blood
  RZ 51/02    2002            Johor                 m     swab
  RZ 69/02    2002            Perak                 m     blood
  RZ 94/02    2002            Perak                 m     blood
  RZ 95/02    2002            Perak                 m     blood
  RZ 107/02   2002            Perak                 m     blood
  RZ 130/02   2002            Sarawak               m     blood
  RZ 143/02   2002            Perak                 m     blood
  RZ 144/02   2002            Perak                 m     blood
  RZ 145/02   2002            Perak                 m     blood
  RZ 176/02   2002            Selangor              f     blood
  RZ 194/02   2002            Pahang                f     blood
  RZ 203/02   2002            Perak                 m     blood
  RZ 207/02   2002            Penang                m     pus
  RZ 15/03    2003            Perak                 m     urine
  RZ 51/03    2003            Perak                 f     blood
  RZ 58/03    2003            Penang                f     blood
  RZ 76/03    2003            Penang                m     blood
  RZ 4/05     2005            Johor                 m     NA
  RZ 5/05     2005            Pahang                m     NA
  RZ 7/05     2005            Pahang                f     NA
  RZ 11/05    2005            Sarawak               m     NA
  RZ 14/05    2005            Sarawak               m     NA
  RZ 15/05    2005            Sarawak               m     NA
  RZ 18/05    2005            Johor                 m     NA
  RZ 46/05    2005            Sarawak               m     NA
  RZ 49/05    2005            Perlis                m     NA
  RZ 50/05    2005            Sarawak               m     NA
  RZ 52/05    2005            Perak                 f     NA
  RZ 61/05    2005            Sabah                 f     NA
  RZ 76/05    2005            Johor                 f     NA
  RZ 77/05    2005            Perak                 m     NA
  RZ 85/05    2005            Johor                 m     NA
  RZ 86/05    2005            Johor                 m     NA
  RZ 87/05    2005            Pahang                m     NA
  RZ 88/05    2005            Sabah                 f     NA
  RZ 77/06    2006            Johor                 m     blood
  RZ 97/06    2006            Selangor              m     blood
  RZ 102/06   2006            Johor                 m     Blood
  RZ 125/06   2006            Johor                 m     Blood
  B 146/06    2006            Pahang                m     Blood
  B 149/06    2006            Pahang                m     Blood
  B 150/06    2006            Pahang                m     Pus
  B 151/06    2006            Pahang                m     Blood
  B 152/06    2006            Pahang                m     Blood
  B 153/06    2006            Kedah                 m     Blood
  B 154/06    2006            Kedah                 m     Blood
  B 155/06    2006            Kedah                 f     Blood
  B 156/06    2006            Kedah                 f     Pus
  B 158/06    2006            Pahang                m     Blood
  B 159/06    2006            Pahang                f     Blood
  B 160/06    2006            Pahang                m     Blood
  B 161/06    2006            Pahang                m     Blood
  B 162/06    2006            Pahang                m     Blood
  B 164/06    2006            Pahang                m     Blood
  B 168/06    2006            Perak                 m     Blood
  B 169/06    2006            Pahang                m     Blood
  B 170/06    2006            Kedah                 f     Pus
  B 171/06    2006            Kedah                 m     Blood
  B 172/06    2006            Pahang                m     Blood
  B 174/06    2006            Perak                 m     Blood
  B 175/06    2006            Perak                 m     Pus
  B 176/06    2006            Perak                 m     Urine
  B 177/06    2006            Kedah                 m     Blood
  B 178/06    2006            Kedah                 f     Blood
  B 179/06    2006            Kedah                 m     Aspirate
  B 180/06    2006            Kedah                 m     Blood
  B 181/06    2006            Kedah                 m     Blood
  B 183/06    2006            Kedah                 m     Blood
  B 184/06    2006            Kedah                 m     Pus
  RZ 3/07     2007            Pahang                m     Blood
  RZ 7/07     2007            Penang                m     Blood
  RZ 8/07     2007            Penang                m     Blood
  RZ 9/07     2007            Penang                m     Blood
  RZ 19/07    2007            Johor                 m     Blood
  RZ 57/07    2007            Selangor              f     NA
  RZ 162/07   2007            Sarawak               f     Blood
  RZ 191/07   2007            Selangor              m     Blood
  RZ 355/07   2007            Johor                 m     Blood
  B 185/07    2007            Kedah                 m     Blood
  B 186/07    2007            Kedah                 m     Blood
  B 187/07    2007            Kedah                 m     Blood
  B 191/07    2007            Penang                m     Blood
  B 192/07    2007            Kedah                 m     Blood
  B 193/07    2007            Selangor              m     NA
  B 194/07    2007            Selangor              f     NA
  B 195/07    2007            Johor                 f     Blood
  B 196/07    2007            Johor                 m     Blood
  B 197/07    2007            Johor                 m     Blood
  B 198/07    2007            Perak                 m     Blood
  B 199/07    2007            Perak                 m     Blood
  B 200/07    2007            Perak                 m     Blood
  B 201/07    2007            Perak                 m     Blood
  B 202/07    2007            Johor                 m     Blood
  RZ 27/08    2008            Sarawak               m     Blood
  RZ 61/08    2008            Sarawak               m     Blood
  RZ 64/08    2008            Sarawak               m     Blood
  RZ 72/08    2008            Selangor              m     Blood
  RZ 76/08    2008            Sarawak               m     knee aspirate
  RZ 77/08    2008            Sarawak               f     Sputum
  RZ 91/08    2008            Selangor              m     Blood
  RZ 96/08    2008            Pahang                f     Blood
  RZ 107/08   2008            Selangor              f     Peritoneal fluid
  RZ 115/08   2008            Sarawak               m     Abscess
  RZ 118/08   2008            Sarawak               m     Blood
  RZ 120/08   2008            Sarawak               m     Blood
  RZ 160/08   2008            Pahang                f     Blood
  RZ 179/08   2008            Sarawak               m     Blood
  RZ 196/08   2008            Sarawak               m     Urine
  RZ 269/08   2008            Johor                 f     Blood
  RZ 276/08   2008            Sarawak               m     Blood
  RZ 299/08   2008            Sarawak               m     Pus
  RZ 305/08   2008            Sarawak               m     Blood
  RZ 307/08   2008            Johor                 m     Tissue
  RZ 365/08   2008            Sarawak               m     Blood
  HB 1/09     2009            Pahang                m     Abscess
  RZ 9/09     2009            Selangor              m     Blood
  RZ 43/09    2009            Sarawak               f     Blood
  RZ 116/09   2009            Wilayah Persekutuan   f     Blood
  RZ 117/09   2009            Wilayah Persekutuan   f     Blood
  RZ 118/09   2009            Wilayah Persekutuan   f     Blood
  RZ 167/09   2009            Sarawak               m     Urine
  RZ 168/09   2009            Sarawak               f     Sputum
  RZ 169/09   2009            Sarawak               m     Blood
  RZ 170/09   2009            Sarawak               m     Blood
  RZ 193/09   2009            Sarawak               m     Blood
  RZ 197/09   2009            Selangor              m     Urine
  RZ 207/09   2009            Selangor              m     Sputum
  RZ 210/09   2009            Pahang                m     Blood
  RZ 267/09   2009            Selangor              m     liver aspirate
  RZ 367/09   2009            Johor                 m     Blood
  RZ 369/09   2009            Sarawak               f     Blood
  RZ 370/09   2009            Sarawak               m     Blood
  RZ 465/09   2009            Sarawak               m     Blood
  RZ 466/09   2009            Sarawak               m     Blood
  MZ 7/10     2010            Wilayah Persekutuan   m     Abscess
  RZ 60/10    2010            Sarawak               f     Blood
  RZ 61/10    2010            Sarawak               f     Blood
  RZ 97/10    2010            Selangor              m     Pus
  RZ 104/10   2010            Sarawak               f     Blood
  RZ 154/10   2010            Johor                 m     Blood
  RZ 158/10   2010            Sarawak               m     Blood
  RZ 161/10   2010            Johor                 m     Blood
  RZ 162/10   2010            Johor                 f     Blood
  RZ 164/10   2010            Sarawak               f     Pus
  RZ 181/10   2010            Selangor              m     Blood
  RZ 193/10   2010            Sarawak               m     Blood
  RZ 205/10   2010            Pahang                m     Blood
  RZ 206/10   2010            Pahang                m     Blood
  RZ 207/10   2010            Pahang                m     Blood
  RZ 208/10   2010            Pahang                m     Blood
  RZ 209/10   2010            Pahang                m     Blood
  RZ 210/10   2010            Selangor              m     Blood
  RZ 229/10   2010            Sarawak               m     pus
  RZ 236/10   2010            Perlis                m     blood
  RZ 265/10   2010            Sarawak               m     blood
  RZ 272/10   2010            Wilayah Persekutuan   m     blood
  RZ 273/10   2010            Sarawak               m     blood
  MZ 17/10    2010            Selangor              m     knee aspirate
  MZ 24/10    2010            Pahang                m     pus

NA: not available.

###### 

The MIC of antibiotics against 170 *Burkholderia pseudomallei* isolates.

  Antibiotic   No. of isolates with the MIC (*µ*g/mL) of   MIC (*µ*g/mL)   %S                                                                          
  ------------ ------------------------------------------- --------------- ---- ---- ---- ---- ----- ---- ---- ---- ---- --- --- --- --- ------ ------ ------
  AMC                                                                                     39   118   9    3                          1   2.0    3.0    99.4
  CAZ                                                                           1    11   75   65    15   2                          1   1.5    2.0    99.4
  CIP                                                                      7    23   42   56   28    10        2         1           1   1.5    2.0    42.3
  CHL                                                                                          1     14   37   81   31   4   1   1       6.0    8.0    96.5
  SXT          18                                          14              19   16   28   24   34    10   5    2                         1.0    2.0    90
  DOX          1                                           10              11   26   48   48   20    4    1         1                    1.0    2.0    99.4
  IMI          48                                          114             7                                   1                         0.38   0.38   99.4
  MEM                                                      2               12   98   49   8    1                                         0.75   1.0    100
  TZP                                                                      2         50   99   16    1    2                              1.5    2.0    100
  SAM                                                                                     1    47    99   20   1    1                1   3.0    4.0    99.4
  TIG                                                      5               15   6    13   32   39    36   19   4    1                    1.5    4.0    64.7

AMC: amoxicillin/clavulanic acid; CAZ: ceftazidime; CIP: ciprofloxacin; CHL: chloramphenicol; SXT: trimethoprim-sulfamethoxazole; DOX: doxycycline; IMI: imipenem; MEM: meropenem; TZP: piperacillin/tazobactam; SAM: ampicillin/sulbactam; TIG: tigecycline.
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